Breast cancer remains the most prevalent malignancy among women globally, manifesting a wide spectrum of clinical outcomes. Early-stage, localized breast cancer typically boasts favorable prognoses, yet the advent of metastatic dissemination drastically diminishes survival prospects. While factors such as cancer subtype and hormone receptor status have long been recognized for their prognostic value, emerging evidence emphasizes the critical role of intercellular communication within the tumor microenvironment. This complex cellular crosstalk enables cancer cells to manipulate their surroundings, facilitating metastatic spread and resistance to conventional therapies.

Central to this communication network is the protein Jagged1, previously identified as highly expressed in aggressive, hormone receptor-negative breast cancers. However, the specific functional contributions of Jagged1 in breast cancer progression had remained elusive until now. In their novel investigation, doctoral researcher Marjaana Parikainen and colleagues demonstrate that Jagged1 not only exacerbates tumor growth but also accelerates metastasis, correlating with poorer survival in patients afflicted with aggressive breast cancer phenotypes.

Employing a comprehensive array of cancer models enriched by clinical breast cancer patient data, the research team uncovered an uncharted mode of cellular dialogue between malignant breast cells and fibroblasts mediated by Jagged1. Fibroblasts, the architects of the extracellular matrix (ECM), play a fundamental role in maintaining tissue architecture and regulating cellular behavior through the ECM’s structural components and signaling molecules. The study reveals that the presence of Jagged1 on breast cancer cells spurs adjacent fibroblasts into an activated state that elevates the production of collagen and remodels the ECM to favor tumor progression.

This Jagged1-induced fibroblast activation leads to pronounced structural alterations in the ECM, notably the alignment of collagen fibers into linear tracks. These aligned fibers act as conduits, facilitating directional migration of cancer cells and thereby enhancing their metastatic potential. Such matrix remodeling significantly influences tissue stiffness — a biomechanical property long recognized to impact cancer cell behavior and therapy response.

Delving deeper into the molecular cascade, the researchers illuminated a critical link between Jagged1 expression and the activation of the transforming growth factor beta (TGFβ) signaling pathway. TGFβ is an established master regulator implicated in late-stage breast cancer progression, known for promoting fibrosis, elevating matrix stiffness, and fostering metastatic dissemination. Their findings reveal that Jagged1 amplifies TGFβ activity, leading to intensified collagen deposition and ECM linearization, thereby creating a microenvironment conducive to cancer cell invasion.

Remarkably, the study also uncovers a self-perpetuating feedback loop where increased matrix stiffness further upregulates Jagged1 expression on cancer cells. This mechanosensitive response, coupled with TGFβ’s known role in inducing Jagged1, establishes a vicious cycle that continuously drives tumor aggression and remodeling. Consequently, the tumor microenvironment evolves dynamically, reinforcing malignant phenotypes and fostering therapeutic resistance.

The implications of these insights are profound, not only deepening our understanding of the tumor-stroma interplay but also highlighting Jagged1 as a promising therapeutic target. Interrupting this feedback mechanism could disrupt the pro-tumorigenic remodeling of the ECM, impeding metastasis and potentially enhancing the efficacy of existing treatments for triple-negative and hormone receptor-negative breast cancers, which currently pose significant clinical challenges.

Collaboration with Professor Jyrki Heino’s research group at the University of Turku fortified the multidisciplinary approach of this investigation, combining expertise in cell biology, extracellular matrix biochemistry, and oncology. Funding support from prominent Finnish foundations and the Research Council of Finland underscores the national commitment to combating breast cancer through innovative research.

Published in the high-impact journal Science Advances on March 18, 2026, this study marks a significant advance in cancer biology. It underscores the necessity of targeting not only cancer cells but also their microenvironmental communication networks and biomechanical context to achieve comprehensive cancer control.

Looking forward, the elucidation of Jagged1’s role invites further exploration into the development of inhibitors or modulators that can selectively target this molecular interaction axis. Such targeted therapies could revolutionize management strategies for aggressive breast cancer forms, aligning with the broader aims of personalized medicine.

The InFLAMES Research Flagship’s integrative approach exemplifies the power of combining immunological and molecular research to unlock novel diagnostic and therapeutic pathways. As more is uncovered about tumor microenvironment dynamics, it becomes increasingly evident that multi-faceted intervention strategies will be key to overcoming cancer metastasis and resistance.

For further information, inquiries can be directed to doctoral researcher Marjaana Parikainen or Professor Cecilia Sahlgren at Åbo Akademi University, whose contact details are available to facilitate academic collaborations and media engagement.

Subject of Research: Cells

Article Title: Jagged1 regulates extracellular matrix deposition and remodeling in triple-negative breast cancer

News Publication Date: 18-Mar-2026

Web References: 10.1126/sciadv.aea9562

Keywords: Breast Cancer, Jagged1, Tumor Microenvironment, Extracellular Matrix, Fibroblasts, TGFβ Pathway, Metastasis, Matrix Remodeling, Cancer Progression, Triple-Negative Breast Cancer, Tumor Stiffness, Cell–Cell Communication

Triple-negative breast cancer presents a formidable challenge due to its lack of hormone receptors and HER2 expression, effectively eliminating many targeted therapy options available for other breast cancer subtypes. This aggressive malignancy disproportionately affects younger women and is associated with poor prognosis, high rates of recurrence, and widespread metastasis. The molecular intricacies of TNBC have long hindered effective treatment, making the identification of innovative therapeutic targets a crucial priority in oncology research.

The study spearheaded by Dr. Sanjay V. Malhotra, Ph.D., co-director of the Center for Experimental Therapeutics at the OHSU Knight Cancer Institute, elucidates the unique mechanism by which SU212 acts. Unlike traditional orthosteric inhibitors that bind directly to the active site of target enzymes, SU212 operates through a non-orthosteric mode of inhibition. This subtler engagement induces the degradation of ENO1 rather than mere enzymatic blockade, ultimately suppressing tumor growth and metastatic spread in vivo. This level of mechanistic insight lends significant weight to SU212’s potential clinical utility.

Enolase 1 plays a fundamental role in glycolysis, the metabolic pathway by which glucose is converted into energy, a process that cancer cells notoriously upregulate to fuel their rapid proliferation. ENO1 overexpression in cancerous tissues amplifies glycolytic flux, thus contributing to tumor survival and aggressiveness. By targeting ENO1 for degradation, SU212 disrupts this metabolic advantage, effectively impairing the energy homeostasis critical for cancer cell viability and dissemination.

The research team employed humanized mouse models, which are mice engineered to carry human immune cells, thus more accurately replicating the complex interactions between tumor cells and the immune system found in patients. The application of such advanced models enhances the translational relevance of SU212’s efficacy, providing a more precise prediction of its therapeutic potential in humans.

Of notable significance is the molecule’s dual relevance in cancer and metabolic diseases. Since ENO1 is intrinsically linked to glucose metabolism, SU212 might offer distinct advantages for patients battling concurrent metabolic disorders such as diabetes. This intersection is particularly important, given the epidemiological convergence of diabetes and cancer, where hyperglycemia potentially exacerbates tumor progression.

As the preclinical data mounts, the imperative next steps involve advancing SU212 into clinical trials—a process that demands rigorous toxicological profiling, formulation optimization, and substantial investment to navigate regulatory pathways. Dr. Malhotra emphasizes this transition as imperative, underscoring the urgency to translate these findings rapidly from bench to bedside to address the unmet medical needs of TNBC patients.

Beyond triple-negative breast cancer, the modulatory effect of SU212 on ENO1 holds promise for other malignancies characterized by ENO1 dysregulation. These include gliomas, which are aggressive brain tumors; pancreatic ductal adenocarcinoma, notorious for poor prognosis; and thyroid carcinoma. The broad applicability underscores a potential paradigm shift in oncology wherein metabolic vulnerabilities become exploitable therapeutic targets across multiple cancer types.

Dr. Malhotra’s journey from the National Cancer Institute and subsequently Stanford University to OHSU reflects a dedicated pursuit of translating complex molecular insights into tangible clinical solutions. His leadership at OHSU’s Center for Experimental Therapeutics is emblematic of the institution’s commitment to pioneering innovative cancer therapies by bridging rigorous scientific investigation with clinical trial initiation.

The implications of SU212’s mechanism extend beyond direct cytotoxicity. By promoting the degradation of ENO1, there is theoretical potential for SU212 to alleviate the immunosuppressive tumor microenvironment, thus potentially augmenting immune-mediated tumor clearance. This prospect opens avenues for combinatorial therapies integrating SU212 with immuno-oncology agents.

Funding for this research has been robust, harnessing support from prominent institutions including the National Cancer Institute, the National Institute on Aging, the National Heart, Lung, and Blood Institute, alongside the Department of Defense and OHSU’s own Biomedical Innovation Program. This multidisciplinary backing underscores the high relevance and interdisciplinary nature of the project.

All animal studies conducted adhered strictly to ethical standards as overseen by OHSU’s Institutional Animal Care and Use Committee (IACUC), ensuring rigorous review of scientific value, humane treatment, and safety protocols, both for the animal models and research personnel. Compliance with these ethical frameworks is paramount in maintaining research integrity and societal trust.

The advent of SU212 marks a hopeful milestone in the grueling battle against triple-negative breast cancer. While challenges remain in translating these promising findings into approved therapeutics, the precise targeting of cancer metabolism through novel biochemical strategies presents a compelling frontier in oncology. Continued research and clinical validation may soon offer new hope to patients facing this devastating disease.

Subject of Research: People

Article Title: Non-orthosteric inhibition of enolase 1 impedes growth of triple-negative breast cancer

News Publication Date: 7-Nov-2025

Web References:

• OHSU Center for Experimental Therapeutics
• Cell Reports Medicine Article
• Triple-negative breast cancer definition

References:
Malhotra, S.V., et al. (2025). Non-orthosteric inhibition of enolase 1 impedes growth of triple-negative breast cancer. Cell Reports Medicine. DOI: 10.1016/j.xcrm.2025.102451

Image Credits: Oregon Health & Science University

Keywords: Breast cancer, Triple-negative breast cancer, Enolase 1, Cancer metabolism, Metastasis

Triple-negative breast cancer, characterized by the absence of estrogen receptors, progesterone receptors, and HER2 expression, represents approximately 15-20% of all breast cancers. It is notorious for its rapid progression, poor differentiation, and lack of targeted hormonal therapies, making early and accurate diagnosis critical. Historically, debate has ensued over whether routine mammographic screening benefits this subgroup in the same capacity as it does hormone receptor-positive breast cancers. The study in question rigorously examines this issue by comparing screen-detected and symptomatic TNBC cases across clinical, radiological, and pathological parameters.

The research team retrospectively analyzed 353 patients with histologically confirmed triple-negative breast cancer diagnosed over seven years from 2013 to 2020 at a single, high-volume oncology institution in Turin. The cases were stratified based on the mode of discovery: those identified via routine mammographic screening versus those diagnosed following reported symptoms. This approach enabled a direct comparative analysis of tumor characteristics, staging, and survival outcomes, including disease-free survival (DFS) and overall survival (OS).

Crucially, approximately half of the studied cohort—50.1%—were detected through screening programs, reflecting a substantial population for robust statistical comparison. The study revealed that screen-detected tumors were predominantly smaller in size, with 96.6% characterized as T1 or T2, compared to only 75% in the symptomatic group. This indicates a significant stage shift towards early detection in the screened cohort, underscoring the potential of routine mammography to identify TNBC at more treatable phases.

Node negativity rates likewise favored the screen-detected group, with 62.4% showing no lymph node involvement versus 48% in symptomatic cases. This observation is paramount as nodal status remains one of the most critical prognostic factors in breast cancer, influencing treatment decisions and survival projections. Additionally, lower overall diagnostic staging—85.4% at an earlier stage in screened participants compared to 63.8% in those presenting symptomatically—further establishes the clinical benefit of early detection through screening.

Despite these encouraging pathological differences, the study’s survival analyses present a more complex picture. Initial univariate evaluations demonstrated better disease-free and overall survival rates for the screen-detected group. However, when adjusting for confounders such as stage at diagnosis, vascular invasion, histologic subtype, and tumor-infiltrating lymphocytes (TILs) via multivariate Cox proportional hazards models, the influence of detection method alone diminished. This suggests that the survival advantage observed may be primarily attributable to the earlier disease stage rather than intrinsic biological disparities between screen-detected and symptomatic tumors.

Interestingly, the investigation found no significant differences in radiological or biological markers—including the density and morphology of tumors or immune cell infiltration—between the two groups. This lack of distinctive tumor biology challenges previous assumptions that screen-detected TNBC might inherently possess less aggressive characteristics and supports the notion that screening facilitates stage migration rather than the detection of fundamentally different tumor phenotypes.

Vascular invasion, a known indicator of tumor aggressiveness and metastatic potential, emerged as an independent prognostic factor, reinforcing its role in risk stratification and treatment planning for TNBC patients. Similarly, histologic type and the presence of TILs—a surrogate marker of the host immune response—were significant predictors of patient outcomes. These findings emphasize the multifaceted nature of TNBC prognosis, extending beyond the simplistic binary of screen-detected versus symptomatically diagnosed cases.

From a clinical perspective, these results advocate for the continued utilization and potential enhancement of mammographic screening programs to capture TNBC cases earlier. Screening’s capability to identify smaller, node-negative tumors holds profound implications for therapeutic intervention effectiveness and overall patient survival. However, the study cautions against overinterpretation of screening as an inherently prognostic factor absent its effect on tumor stage, urging clinicians to consider a broader biological context during patient management.

The results also highlight the persistent challenge posed by triple-negative breast cancer’s biological heterogeneity. Although early detection improves outcomes through tumor size and nodal status shifts, TNBC’s aggressive behavior requires continued research into targeted therapies, immune modulation, and personalized medicine approaches. Integration of predictive biomarkers and immune landscape analysis may refine prognostic assessments and inform novel treatment paradigms.

Epidemiologically, the findings reinforce the broader public health imperative of maintaining population-wide breast cancer screening schemes. Expanding access and adherence to mammographic screening could particularly benefit subgroups at high risk for TNBC, such as younger women and those with genetic predispositions. Nevertheless, the study suggests that integrating molecular profiling with imaging findings could further stratify risk and optimize resource allocation.

Technical aspects of the study incorporate robust statistical methodologies, including Kaplan-Meier survival curves to visualize temporal differences in DFS and OS, complemented by Cox proportional hazards modeling to adjust for confounding variables. This comprehensive analytical framework lends credibility to the conclusions drawn, helping delineate the complex relationships between screening, tumor biology, and patient outcomes in TNBC.

In light of these findings, future research directions might involve prospective cohort studies across diverse populations to validate results and assess the impact of emerging imaging technologies such as digital breast tomosynthesis or MRI in early TNBC detection. Furthermore, mechanistic studies investigating how immune microenvironment factors, like TILs, influence tumor progression after early detection could unlock therapeutic possibilities.

Ultimately, the study underscores that the survival advantage associated with screen-detected triple-negative breast cancer is rooted in earlier stage diagnosis rather than fundamental differences in tumor biology. These insights have meaningful implications for clinical practice, screening policies, and ongoing research efforts aimed at improving prognosis for one of breast cancer’s most formidable subtypes.

The integration of radiological vigilance with pathological and immunological profiling will likely be essential in overcoming the challenges of TNBC, forging paths toward improved survival through personalized and timely interventions. As technological and therapeutic landscapes evolve, understanding the nuanced interplay between detection methods and tumor characteristics remains a critical frontier for oncologists and researchers alike.

In conclusion, this pivotal study illuminates the complexity behind triple-negative breast cancer prognosis, affirming the value of early detection while highlighting the multidimensional factors that ultimately dictate patient outcomes. As the global medical community strives to combat breast cancer mortality, such evidence-based analyses provide indispensable guidance toward optimizing screening practices and tailoring care specifically for aggressive disease variants like TNBC.

Subject of Research: Early detection impact and prognostic analysis of triple-negative breast cancer comparing screen-detected versus symptomatic cases.

Article Title: Early detection of triple-negative breast cancer: evidence of a favourable prognostic impact in a comparative analysis of screen-detected versus symptomatic cases.

Article References:
Castellano, I., Rousset, S., Casella, D. et al. Early detection of triple-negative breast cancer: evidence of a favourable prognostic impact in a comparative analysis of screen-detected versus symptomatic cases. BMC Cancer 25, 730 (2025). https://doi.org/10.1186/s12885-025-14067-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14067-2